Metagenomi Therapeutics, Inc. Common Stock (MGX) — 分析摘要
Metagenomi Therapeutics, Inc. Common Stock（MGX）的市值为49.69百万美元，最近一年的营收同比增长了-51.8%。净利润率为-348.5%。当前市盈率为-0.6倍。
核心要点
- 营收同比变化-51.8%
- 净利润率-348.5%
- 市盈率-0.6倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比，MGX的营收增长为-51.8%，市盈率为-0.6倍。
Metagenomi Therapeutics, Inc. Common Stock (MGX)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -415.5% — 严重经营亏损
净利率为 -384.6% — 亏损超过收入（可能含一次性费用）
营收较上一期下降 11.4%。
最新报表显示自由现金流为负。
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
118
总部
EMERYVILLE, CA
Exchange
XNAS
需要至少 3 年年度财务数据来评估竞争壁垒。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。